Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma.

Trial Profile

Phase I/II Study Of The Combination Of Lenalidomide With High-Dose Melphalan For Autologous Transplant in Patients With Multiple Myeloma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Lenalidomide (Primary) ; Melphalan (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Updated results (39.8 months of follow up) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 30 Mar 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov
    • 08 Mar 2015 Status changed from active, no longer recruiting to discontinued, according to M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top